Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Nuki

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Health and Quality of Life Outcomes|September 25, 2012
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyPuja P Khanna, George Nuki, Thomas Bardin, et al.
Annals of the Rheumatic Diseases|August 7, 2012
Gout: why is this curable disease so seldom cured?Michael Doherty, Tim L Jansen, George Nuki, et al.
Nature Reviews. Rheumatology|August 20, 2014
Improving cardiovascular and renal outcomes in gout: what should we target?Pascal Richette, Fernando Perez-Ruiz, Michael Doherty, et al.
BMJ Open Gastroenterology|May 9, 2020
Prevalence and sociodemographic determinants of dyspepsia in the general population of RwandaJean Bosco Bangamwabo, John David Chetwood, Vincent Dusabejambo, et al.
Seminars in Arthritis and Rheumatism|February 25, 2014
Up-titration of allopurinol in patients with goutClaudine G Jennings, Isla S Mackenzie, Rob Flynn, et al.
Contemporary Clinical Trials|February 10, 2025
Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studiesKenneth G Saag, Nicola Dalbeth, Chi-Yuan Hsu, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Osteoarthritis and Cartilage|March 17, 2004
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritisEric Abadie, Dominique Ethgen, Bernard Avouac, et al.
Annals of the Rheumatic Diseases|June 7, 2019
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of goutPascal Richette, Michael Doherty, Eliseo Pascual, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Health and Quality of Life Outcomes|September 25, 2012
Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyPuja P Khanna, George Nuki, Thomas Bardin, et al.
Annals of the Rheumatic Diseases|August 7, 2012
Gout: why is this curable disease so seldom cured?Michael Doherty, Tim L Jansen, George Nuki, et al.
Nature Reviews. Rheumatology|August 20, 2014
Improving cardiovascular and renal outcomes in gout: what should we target?Pascal Richette, Fernando Perez-Ruiz, Michael Doherty, et al.
BMJ Open Gastroenterology|May 9, 2020
Prevalence and sociodemographic determinants of dyspepsia in the general population of RwandaJean Bosco Bangamwabo, John David Chetwood, Vincent Dusabejambo, et al.
Seminars in Arthritis and Rheumatism|February 25, 2014
Up-titration of allopurinol in patients with goutClaudine G Jennings, Isla S Mackenzie, Rob Flynn, et al.
Contemporary Clinical Trials|February 10, 2025
Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: Design of the EURELIA 1 and EURELIA 2 studiesKenneth G Saag, Nicola Dalbeth, Chi-Yuan Hsu, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Osteoarthritis and Cartilage|March 17, 2004
Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritisEric Abadie, Dominique Ethgen, Bernard Avouac, et al.
Annals of the Rheumatic Diseases|June 7, 2019
2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of goutPascal Richette, Michael Doherty, Eliseo Pascual, et al.
Pageof 3